A study of 3,307 patients with castration-resistant prostate cancer that had spread to the bones found that prolonged denosumab treatment was associated with a higher risk of jawbone necrosis. The patients received the drug to reduce skeletal complications such as fractures and spinal cord compression. Researchers used health insurance review data and compared treatment lasting six months or less, seven to 12 months, and at least 13 months.

The three-year cumulative risk of jawbone necrosis was 3.28% among patients treated for seven to 12 months. It rose to 12.20% among those treated for at least 13 months, about 3.7 times higher. By contrast, the risks of skeletal complications were similar in the two groups: 3.82% and 3.99%, respectively, suggesting no additional reduction after treatment extended beyond one year in this comparison.

Jawbone necrosis can appear when a wound after tooth extraction fails to heal or when the jawbone becomes exposed. The researchers said denosumab suppresses cells that break down bone, which can help prevent skeletal complications in patients with metastatic cancer. They also noted that long-term suppression may hinder normal bone renewal and make tissue damage harder to repair.

The findings do not mean every patient should stop denosumab immediately after one year. Abrupt discontinuation can produce a rebound increase in bone breakdown, so treatment decisions should consider an individual’s fracture risk and dental treatment history. The researchers said doctors should assess whether treatment should continue and whether dosing intervals should change on a patient-by-patient basis. The study was published in JAMA Network Open.